Defects in the DNA damage response pathways can lead to tumour development. The tumour suppressor p53 is a key player in the DNA damage response, and the precise regulation of p53 is critical for the suppression of tumorigenesis. DNA damage induces the activity of p53, via damage sensors such as ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia-related), which leads to the transcriptional regulation of a variety of genes involved in cell cycle control and apoptosis. p53 is therefore tightly controlled, and its activity is regulated at a multiplicity of levels. An increasing array of cofactors are now known to influence p53 activity. Here we will discuss several of the cofactors that impact on p53 activity, specifically those involved in the function of the two novel p53 cofactors JMY (junction-mediating and regulatory protein) and Strap (serine/threonine-kinase-receptor-associated protein).
Introduction
The p53 gene is one of the most commonly mutated genes in human cancer; approx. 50% of human cancers contain p53 mutations, while the other half are thought to contain alterations in components of the p53 pathway [1] . p53 is a critical human tumour suppressor that plays a key role in the checkpoint response to DNA damage, and the precise regulation of p53 is necessary for both the checkpoint response and the suppression of tumorigenesis. The checkpoint response to DNA damage involves a myriad of cellular activities, including cell cycle arrest, DNA repair and apoptosis, and defects in the DNA damage response pathway lead to tumour development [2] .
The Mdm2 (murine double minute 2) oncoprotein
Mdm2 (or Hdm2 in humans; hereafter referred to as Mdm2) is an important human oncogene and a key regulator of the p53 response, in both the presence and the absence of DNA damage, where it plays a role in negatively regulating p53 activity [6, 7] . Mdm2 binds to the N-terminal region of p53 and represses p53 activity via two main mechanisms: by promoting degradation and by blocking p53 transcriptional activation [8] [9] [10] . The importance of Mdm2 in regulating p53 activity is underscored by the finding that mdm2 −/− mouse embryos die early in development due to massive p53-dependent apoptosis, which is rescued in the mdm2
−/− mouse [6, 7, 11] . Furthermore, because mdm2 transcription is regulated by p53, transcriptional activation by p53 provides an autoregulatory feedback loop [12] . p53 is tightly regulated, and is normally maintained at low levels. After DNA damage, p53 is stabilized and its half-life increases. Because Mdm2 contains within it RING-finger domain E3 ligase activity responsible for p53 ubiquitination and proteasomal degradation, the negative regulation by Mdm2 must be relieved in order for stabilization and nuclear accumulation of p53 to occur. The mechanism of action of the Arf protein, which binds to Mdm2 causing the release of p53, is a paradigm in the regulation of p53, and we refer the reader to several recent reviews on this topic [13, 14] . Similarly, post-translational control of p53 is well documented to influence p53 activity, and again we refer the reader to some excellent reviews [5, 15] .
However, the interaction of Mdm2 with p53 can be influenced by several other groups of proteins ( Figure 1 ). For example, Mdm2 can, under certain circumstances, localize to the nucleolus [16, 17] , and contains within its C-terminal region an NoLS (nucleolar localization) signal [18] . A growing body of evidence supports the fact that nucleolar sequestration of Mdm2 influences p53 activity [19] [20] [21] [22] . More recently, a role for ribosomal proteins has been suggested in regulating the nucleolar localization of Mdm2. Mdm2 has been shown to interact with the ribosomal protein L11 [23] , and this interaction is increased in response to the DNA-damaging agent actinomycin D [24] . L11 prevents Mdm2 ubiquitinating and degrading p53, most probably by inhibiting the E3 ubiquitin ligase activity of Mdm2 [24] . The ribosomal protein L23 also interacts with Mdm2, and L23 and L11 can interact simultaneously with Mdm2 [25, 26] . Reducing the levels of L23 concomitantly increases p53 transcriptional activity [26] , and the overexpression of L23 has been found to inhibit Mdm2-mediated p53 ubiquitination [25] . The ribosomal protein L5 can also interact with Mdm2 [27] , although the functional significance of this interaction has not been determined. Further, the interaction of Mdm2 with L23, L11 and L5 can occur in the cytoplasm [25] . The fact that multiple ribosomal proteins interact with Mdm2 suggests an important link between ribosomal biogenesis and p53 activity, perhaps highlighting a pathway that integrates the p53 response with protein synthesis.
It is known that binding of Mdm2 conceals the N-terminal activation domain of p53 [10] . MdmX, which is a structural homologue of Mdm2, also binds to p53 and inhibits its transcriptional activity [28] . Furthermore, the interaction between Mdm2 and MdmX results in an increased half-life of Mdm2 [29] . Despite this, MdmX blocks Mdm2-mediated p53 degradation [30] . Although the role of MdmX in DNA damage-mediated control of p53 activity remains unclear, Mdm2 targets MdmX for degradation after DNA damage, which appears to be dependent on ATM-directed MdmX phosphorylation [31, 32] . In addition, a role for MdmX in p53-dependent tumour suppressor activity has recently been demonstrated [33] . 
CBP/p300 family of transcriptional co-activators
CBP [CREB (cAMP response element-binding protein) binding protein] and p300 are ubiquitous transcriptional co-activators that interact with a plethora of sequence-specific transcription factors, and a variety of studies support a role for CBP/p300 in regulating p53-dependent transcription. CBP/p300 proteins bind to the p53 activation domain and stimulate p53 transcriptional activity [34] [35] [36] [37] [38] . Further, CBP/p300 proteins are acetyltransferases that acetylate not only chromatin, but also a variety of transcription factors, including p53 [39] . The C-terminal region of p53 contains two sites for acetylation by CBP/p300 and one for the CBP/ p300-associated histone acetyltransferase P/CAF (p300/CBP-associated factor) [40] . It appears that, after DNA damage, p53 is phosphorylated at Ser 15 , which increases the association between CBP/p300 and p53, and thereafter the acetylation of p53 [41] . Although the influence that acetylation has on p53 activity remains unclear, several reports suggest that acetylation increases p53 stability and promotes co-activator recruitment, leading to increased transcriptional activity [35, [42] [43] [44] . Mdm2 prevents the interaction between p53 and p300, and it has also been shown to reduce p53 acetylation by recruiting a histone deacetylase 1 complex that binds Mdm2 and acts synergistically with Mdm2 to reduce the acetylation of p53 [45] . The regulatory events that may impact upon p300 activity are further underscored by the more recent findings that Mdm2 also influences the stability of P/CAF [46] .
In addition, p300 binds to Mdm2, and a role for p300 in the Mdm2-dependent regulation of p53 levels has been suggested [47, 48] . Kobet and co-workers [49] purified a p300-Mdm2-p53 protein complex from HeLa cell nuclear extracts, supporting the existence of a tripartite complex in cells. In addition, Mdm2 is acetylated in vitro by CBP/p300, within its C-terminal RING-finger domain, which may influence p53 degradation by impairing E3 ligase activity [50] .
The JMY cofactor
JMY is a CBP/p300 cofactor that augments the p53 response [51] . The JMY transcript is expressed in a variety of tissues and encodes a protein of 110 kDa with no significant sequence similarity to other known proteins. JMY and p300 interact under physiological conditions, probably as a result of a direct interaction, and two regions in JMY are capable of interacting with p300. The fact that JMY increases p53-dependent transcription and apoptosis provides evidence that JMY plays a functional role in the p53 response. Importantly, ectopic expression of JMY did not alter p53 protein levels, which is consistent with the idea that it functions as a transcriptional cofactor [51] . Furthermore, actinomycin D treatment causes the formation of a complex containing p300, JMY and p53 (Figure 2) , demonstrating the likely importance of JMY in the p53 stress response [51] . Most interestingly, JMY contains a C-terminal proline-rich domain which is absent in certain protein isoforms that display reduced activation of p53-dependent transcription and apoptosis, but co-operate with p53 to promote cell cycle arrest more efficiently than wild-type JMY [51] . It is possible, but as yet unproven, that the JMY expression level and isoform composition influences the properties of the p53 response.
Cofactor Strap
Strap was originally identified as a novel JMY-interacting protein [52] . Notably, Strap contains a tandem series of six TPR (tetratricopeptide) repeats, a motif thought to function in protein-protein interactions [52] . As Strap is composed almost entirely of TPR motifs, it is likely that this protein is involved in regulating and mediating the assembly of multi-protein complexes. In support of this, Strap contains distinct regions that interact with . Phosphorylated Strap is stabilized and undergoes accumulation in the nucleus, where it assembles into a co-activator complex that includes p300 and cofactors such as JMY. A part of the role of Strap is to augment p53 activity through increased acetylation and transcriptional activity, resulting in the activation of DNA damage response genes.
either JMY or p300, and which facilitate the interaction between JMY and p300 [52] . Strap is also involved in the p53 response, and ectopic expression of Strap increases the levels and half-life of endogenous p53. Furthermore, Strap prevents Mdm2-mediated down-regulation of p53 levels and increases p53-dependent apoptosis, providing further evidence for an important role for Strap in regulating the p53 response [52] .
More recently, the DNA-damage-responsive ATM kinase was found to phosphorylate Strap, causing increased nuclear accumulation and association with p300 [53] . Specifically, ATM phosphorylates Strap at Ser
203
, and this is important in the control of Strap stability and subcellular localization ( Figure  2) . Consistent with this, in AT (ataxia telangiectasia) cells, which have missing or inactive ATM kinase, Strap remains cytoplasmic and cannot locate to the nucleus during DNA damage. In normal cells, the DNA damage-dependent increase in Strap prompts p53 acetylation through recruitment of p300/ JMY, thereafter enhancing p53-dependent apoptosis [53] . This requires ATM-dependent phosphorylation, since a mutant derivative of Strap lacking the ATM phosphorylation site has a reduced effect on p53 [53] . These studies have elucidated a new DNA damage-responsive co-activator complex that integrates upstream signals derived from the ATM family of sensor kinases with the transcription apparatus.
Chromatin-modulating proteins
Because p53 acts as a transcription factor, chromatin needs to be modified in order to facilitate changes in transcriptional activity. As discussed above, the p300/ CBP co-activators, upon recruitment to p53, acetylate both the local chromatin environment and p53 itself [39] . In addition to p300, other distinct co-activator complexes have been shown to function in p53-dependent transcription, including the SAGA (Spt/Ada/Gcn5 acetyltransferase) and NuA4-Tip60 complexes (reviewed in [54] ), whose common subunit, the ATM-related protein TRRAP (transformation/transcription domain-associated protein), binds directly to p53 and is involved in p53-dependent transcription [55] . However, in a similar fashion to the role of acetylation in gene activation, histone lysine and arginine methylation are enzymatic events that influence gene expression [56] . The arginine methyltransferases CARM1 (co-activator-associated arginine methyltransferase 1) and PRMT1 (protein-arginine N-methyltransferase 1) have been implicated in p53 transcription, where they co-operate with p300 in activating the GADD45 (growth arrest and DNA damage-inducible protein) gene and assemble with the GADD45 promoter during the p53 response [57] . Interestingly, PRMT1 and p300 both interact with the N-terminal region of p53, whereas CARM1 binds preferentially to the C-terminal region of p53 [57] .
An important question relates to the interplay between chromatin modulators such as PRMT1 and CARM1, and cofactors such as JMY and Strap. Is there, for example, any sequential control and temporal order in the assembly of co-activator complexes at p53-responsive promoters, or do different factors act in a gene-specific fashion? We await the answers to these interesting questions. 
Conclusions
It has become increasingly clear that numerous p53 cofactors exist that exert positive and negative effects on p53 activity. Although a more complete understanding of the factors themselves and signals that control their activity is required in order to gain a greater understanding of the multiple regulatory levels that p53 is subjected to, we can, nevertheless, reach some general conclusions. For example, subnuclear localization of both p53 and its various cofactors clearly plays an important role in the DNA damage response. Significantly, the nucleolus and nucleolar proteins are important players in the response of p53 after DNA damage, and the list of nucleolar proteins capable of affecting the p53 response continues to expand. Future research will no doubt shed light on the signals that govern these interactions, and the spatial and temporal influences on p53 activity.
An important area of research that needs to be explored more fully is the role of tissue-specific differences in the levels of p53 cofactors in tumour development and therapeutic responses. Similarly, differences in the tissue-specific distribution of the p53 cofactors JMY and Strap may contribute to the differing response of p53 to damaging agents. We suspect that a more complete understanding of the regulation of the factors that can control p53 activity will be of significance in developing a better understanding of therapeutic strategies to treat cancer.
Further, the interplay between cofactors in the regulation of p53-dependent genes, particularly chromatin control, is likely to yield important insights into the DNA damage response. We have only discussed a few of the numerous cofactors that assemble with and influence p300/CBP activity. A detailed understanding of the interplay between these factors and their role in the p53 response will undoubtedly uncover new complexities in p53 control. We await with interest information on the pathways and physiological cues that control the expanding group of cofactors implicated in p53 regulation.
